Novartis AG Common Stock (NVS)

Cost of Revenue

$14.22B

TTM · Period ending: · USD

NVS logo

NVS Cost of Revenue

Latest reported$14.22B
NVS TTM Cost of Revenue ($1.06B → $14.22B)
High-resolution chart · PNG

NVS cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novartis AG Common Stock Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
14,220,252,000
13,861,731,000
13,629,731,000
13,412,000,000
13,107,000,000
12,958,000,000
12,827,000,000
12,525,000,000
12,408,000,000
12,577,000,000
12,472,000,000
13,523,000,000
13,280,000,000
13,689,000,000
14,554,000,000
14,457,000,000
15,521,000,000
15,684,000,000
15,867,000,000
16,108,000,000
15,923,000,000
15,438,000,000
15,121,000,000
14,896,000,000
14,919,000,000
14,896,000,000
14,425,000,000
15,359,000,000
15,046,000,000
15,198,000,000
15,398,000,000
14,961,000,000
15,821,000,000
16,521,000,000
17,175,000,000
17,175,000,000
17,220,000,000
17,413,000,000
17,520,000,000
17,580,000,000
17,600,000,000
17,636,000,000
17,404,000,000
17,271,000,000
17,304,000,000
17,195,000,000
17,345,000,000
18,241,000,000
17,946,000,000
17,655,000,000
18,131,000,000
17,906,000,000
18,355,000,000
18,878,000,000
18,756,000,000
18,787,000,000
19,000,000,000
19,009,000,000
18,983,000,000
18,389,000,000
17,263,000,000
15,850,000,000
14,488,000,000
13,631,000,000
13,072,000,000
12,690,000,000
12,402,000,000
11,569,000,000
11,487,000,000
11,599,000,000
11,439,000,000
11,618,000,000
11,631,000,000
11,192,000,000
11,032,000,000
10,533,000,000
10,028,000,000
9,756,000,000
9,450,000,000
9,453,000,000
9,374,000,000
9,124,000,000
8,795,000,000
8,160,000,000
7,323,000,000
6,942,000,000
6,625,000,000
6,351,000,000
6,238,000,000
6,067,000,000
5,894,000,000
6,046,000,000
5,757,000,000
5,631,000,000
4,268,000,000
2,508,000,000
1,297,000,000
1,060,000,000
1,060,000,000
1,060,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.